
|Articles|March 31, 2023
Recommendations for Accelerating Cell and Gene Therapies
Author(s)Cognizant
While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
2
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
3
FDA Continues to Expand National Priority Voucher Program
4
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
5


